Orchid Pharma Ltd (ORCHPHARMA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 653435,
    "name": "Orchid Pharma",
    "stock_name": "Orchid Pharma",
    "full_name": "Orchid Pharma Ltd",
    "name_url": "stocks-analysis/orchid-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "699.50",
    "chg": 25.3,
    "chgp": "3.75%",
    "dir": 1,
    "prev_price": "674.20",
    "mcapval": "3,443.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524372,
    "symbol": "ORCHPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE191A01027",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "55.52 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/orchid-pharma-653435-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Orchid Pharma’s Evaluation Metrics Revised Amid Challenging Financial and Market Conditions",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/orchid-pharma-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-outlook-3735202",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OrchidPharma_mojoScore_3735202.png",
        "date": "2025-11-28 10:05:12",
        "description": "Orchid Pharma has experienced a revision in its evaluation metrics reflecting a more cautious market assessment. This shift follows a series of financial and operational challenges that have influenced the company’s standing within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Orchid Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-orchid-pharma-fallingrising-3732074",
        "imagepath": "",
        "date": "2025-11-27 00:29:46",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Outperformance</strong></p>\n<p>Orchid Pharma’s stock has demonstrated a strong upward trajectory over the past month, surging by 21.35%, significantly outperforming the Sensex’s modest 1.66% gain during the same period. This recent rally is further underscored by the stock’s outperformance relative to its sector, with a 2.64% higher return on the day. The stock has also recorded gains for two consecutive days, accumulating a 4.68% increase in that span. Intraday, the share price touched a high of ₹898.45, marking a 6.69% rise from previous levels, signalling robust buying interest.</p>\n<p>Technical indicators support this positive momentum, as Orchid Pharma is trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day ave..."
      },
      {
        "title": "Is Orchid Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-orchid-pharma-technically-bullish-or-bearish-3710247",
        "imagepath": "",
        "date": "2025-11-18 08:30:22",
        "description": "As of 17 November 2025, the technical trend for Orchid Pharma has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook and the monthly MACD showing a bearish signal. While the weekly MACD and KST are mildly bullish, the overall sentiment is tempered by the monthly indicators and the lack of strong signals from the RSI and OBV. The Bollinger Bands present a mixed picture with a bullish weekly stance but a mildly bearish monthly view. Overall, the bearish indicators outweigh the bullish ones, leading to the current mildly bearish assessment...."
      },
      {
        "title": "Orchid Pharma Shows Mixed Technical Signals Amid Market Volatility and Resilience",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/orchid-pharmas-technical-trend-shifts-from-sideways-to-mildly-bearish-amid-mixed-performance-3710521",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OrchidPharma_technicaldot_3710521.png",
        "date": "2025-11-18 08:12:54",
        "description": "Orchid Pharma, a small-cap pharmaceutical company, has seen significant stock price fluctuations, currently priced at 857.95. The stock has experienced a 52-week high of 1,998.00 and a low of 603.80. Its performance over five years shows a substantial return compared to the Sensex, indicating potential resilience."
      },
      {
        "title": "Orchid Pharma Hits Day High with 8.04% Intraday Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/orchid-pharma-hits-day-high-with-804-intraday-surge-3707763",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OrchidPharma_priceRelatedfactors_3707763.png",
        "date": "2025-11-17 15:01:30",
        "description": "Orchid Pharma's stock has surged today, outperforming its sector and achieving consecutive gains over the past two days. Currently trading above key moving averages, the stock has shown a significant long-term increase despite recent declines. The broader market is also experiencing positive momentum, particularly among mid-cap stocks."
      },
      {
        "title": "How has been the historical performance of Orchid Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-orchid-pharma-3694457",
        "imagepath": "",
        "date": "2025-11-12 23:40:13",
        "description": "Answer:\nThe historical performance of Orchid Pharma shows a significant improvement in financial metrics over the years, particularly from March 2023 to March 2025.\n\nBreakdown:\nOrchid Pharma's net sales have steadily increased from 665.90 Cr in March 2023 to 921.93 Cr in March 2025, reflecting a robust growth trajectory. The total operating income followed a similar trend, rising from 665.90 Cr to 921.93 Cr during the same period. The company's operating profit (PBDIT) also improved significantly, increasing from 103.05 Cr in March 2023 to 144.65 Cr in March 2025, although the operating profit margin slightly decreased from 12.56% to 12.71%. Profit before tax rose from 55.25 Cr to 95.56 Cr, and profit after tax increased from 55.25 Cr to 95.76 Cr, indicating a strong recovery from previous losses. The consolidated net profit showed a remarkable increase from 46.32 Cr in March 2023 to 99.66 Cr in March 2025...."
      },
      {
        "title": "Are Orchid Pharma latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-orchid-pharma-latest-results-good-or-bad-3693132",
        "imagepath": "",
        "date": "2025-11-12 19:25:45",
        "description": "Orchid Pharma's latest financial results for the quarter ending September 2025 reveal significant operational challenges. The company reported a consolidated net loss of ₹5.72 crores, a stark contrast to the profit of ₹14.91 crores in the previous quarter, indicating a substantial decline in profitability. Year-on-year, the net profit swung from a profit of ₹27.24 crores in Q2 FY25 to a loss, marking a notable deterioration.\n\nRevenue for the quarter was ₹193.52 crores, reflecting a year-on-year decline of 13.10% from ₹222.70 crores in the same quarter last year. Although there was a sequential growth of 11.91% from the previous quarter's revenue of ₹172.93 crores, this was insufficient to restore profitability. The operating profit turned negative at ₹-1.48 crores, with operating margins collapsing to -0.76%, down from 8.19% in the prior quarter and 13.62% a year ago.\n\nThe gross profit margin also compresse..."
      },
      {
        "title": "Orchid Pharma Q2 FY26: Sharp Quarterly Loss Raises Operational Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/orchid-pharma-q2-fy26-sharp-quarterly-loss-raises-operational-concerns-3692649",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OrchidPharma_quaterlyResult_3692649.png",
        "date": "2025-11-12 09:43:02",
        "description": "Orchid Pharma Ltd., a Chennai-based pharmaceutical company with operations spanning over 40 countries, has reported a consolidated net loss of ₹5.72 crores for Q2 FY26, marking a dramatic reversal from the ₹14.91 crores profit recorded in the previous quarter. The company's shares closed at ₹790.25 on November 12, down 3.87% from the previous session, as investors reacted to the concerning quarterly performance that saw the company slip into operating losses for the first time in recent quarters."
      },
      {
        "title": "Orchid Pharma Hits Day Low of Rs 732 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/orchid-pharma-hits-day-low-of-rs-732-amid-price-pressure-3691826",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OrchidPharma_priceRelatedfactors_3691826.png",
        "date": "2025-11-12 09:32:03",
        "description": "Orchid Pharma's stock has faced notable declines, dropping 8.19% today and marking its second consecutive day of losses. The stock has shown high volatility, with fluctuations reaching 18.28%. Over the past year, it has decreased significantly, contrasting with the overall positive performance of the Sensex."
      }
    ],
    "total": 285,
    "sid": "653435",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/orchid-pharma-653435"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Jan-2026",
      "details": "Compliance certificate under regulation 74(5) of SEBI (Depositories and participants) Regulations for the Quarter-III of F.Y. 2025-26 ended on December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "29-Dec-2025",
      "details": "Intimation of Trading Window Closure for the Quarter III of Financial Year 2025-26 ending on December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "17-Nov-2025",
      "details": "Transcript of Analysts/ Investors Earning call held with public at large on November 11 2025 for the quarter ended September 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Orchid Pharma Ltd has declared <strong>30%</strong> dividend, ex-date: 13 Sep 12",
          "dt": "2012-09-13",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Orchid Pharma’s Evaluation Metrics Revised Amid Challenging Financial and Market Conditions

2025-11-28 10:05:12

Orchid Pharma has experienced a revision in its evaluation metrics reflecting a more cautious market assessment. This shift follows a series of financial and operational challenges that have influenced the company’s standing within the Pharmaceuticals & Biotechnology sector.

Why is Orchid Pharma falling/rising?

2025-11-27 00:29:46

Recent Price Movement and Market Outperformance Orchid Pharma’s stock has demonstrated a strong upward trajectory over the past month, surging by 21.35%, significantly outperforming the Sensex’s modest 1.66% gain during the same period. This recent rally is further underscored by the stock’s outperformance relative to its sector, with a 2.64% higher return on the day. The stock has also recorded gains for two consecutive days, accumulating a 4.68% increase in that span. Intraday, the share price touched a high of ₹898.45, marking a 6.69% rise from previous levels, signalling robust buying interest. Technical indicators support this positive momentum, as Orchid Pharma is trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day ave...

Is Orchid Pharma technically bullish or bearish?

2025-11-18 08:30:22

As of 17 November 2025, the technical trend for Orchid Pharma has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook and the monthly MACD showing a bearish signal. While the weekly MACD and KST are mildly bullish, the overall sentiment is tempered by the monthly indicators and the lack of strong signals from the RSI and OBV. The Bollinger Bands present a mixed picture with a bullish weekly stance but a mildly bearish monthly view. Overall, the bearish indicators outweigh the bullish ones, leading to the current mildly bearish assessment....

Orchid Pharma Shows Mixed Technical Signals Amid Market Volatility and Resilience

2025-11-18 08:12:54

Orchid Pharma, a small-cap pharmaceutical company, has seen significant stock price fluctuations, currently priced at 857.95. The stock has experienced a 52-week high of 1,998.00 and a low of 603.80. Its performance over five years shows a substantial return compared to the Sensex, indicating potential resilience.

Orchid Pharma Hits Day High with 8.04% Intraday Surge

2025-11-17 15:01:30

Orchid Pharma's stock has surged today, outperforming its sector and achieving consecutive gains over the past two days. Currently trading above key moving averages, the stock has shown a significant long-term increase despite recent declines. The broader market is also experiencing positive momentum, particularly among mid-cap stocks.

How has been the historical performance of Orchid Pharma?

2025-11-12 23:40:13

Answer: The historical performance of Orchid Pharma shows a significant improvement in financial metrics over the years, particularly from March 2023 to March 2025. Breakdown: Orchid Pharma's net sales have steadily increased from 665.90 Cr in March 2023 to 921.93 Cr in March 2025, reflecting a robust growth trajectory. The total operating income followed a similar trend, rising from 665.90 Cr to 921.93 Cr during the same period. The company's operating profit (PBDIT) also improved significantly, increasing from 103.05 Cr in March 2023 to 144.65 Cr in March 2025, although the operating profit margin slightly decreased from 12.56% to 12.71%. Profit before tax rose from 55.25 Cr to 95.56 Cr, and profit after tax increased from 55.25 Cr to 95.76 Cr, indicating a strong recovery from previous losses. The consolidated net profit showed a remarkable increase from 46.32 Cr in March 2023 to 99.66 Cr in March 2025....

Are Orchid Pharma latest results good or bad?

2025-11-12 19:25:45

Orchid Pharma's latest financial results for the quarter ending September 2025 reveal significant operational challenges. The company reported a consolidated net loss of ₹5.72 crores, a stark contrast to the profit of ₹14.91 crores in the previous quarter, indicating a substantial decline in profitability. Year-on-year, the net profit swung from a profit of ₹27.24 crores in Q2 FY25 to a loss, marking a notable deterioration. Revenue for the quarter was ₹193.52 crores, reflecting a year-on-year decline of 13.10% from ₹222.70 crores in the same quarter last year. Although there was a sequential growth of 11.91% from the previous quarter's revenue of ₹172.93 crores, this was insufficient to restore profitability. The operating profit turned negative at ₹-1.48 crores, with operating margins collapsing to -0.76%, down from 8.19% in the prior quarter and 13.62% a year ago. The gross profit margin also compresse...

Orchid Pharma Q2 FY26: Sharp Quarterly Loss Raises Operational Concerns

2025-11-12 09:43:02

Orchid Pharma Ltd., a Chennai-based pharmaceutical company with operations spanning over 40 countries, has reported a consolidated net loss of ₹5.72 crores for Q2 FY26, marking a dramatic reversal from the ₹14.91 crores profit recorded in the previous quarter. The company's shares closed at ₹790.25 on November 12, down 3.87% from the previous session, as investors reacted to the concerning quarterly performance that saw the company slip into operating losses for the first time in recent quarters.

Orchid Pharma Hits Day Low of Rs 732 Amid Price Pressure

2025-11-12 09:32:03

Orchid Pharma's stock has faced notable declines, dropping 8.19% today and marking its second consecutive day of losses. The stock has shown high volatility, with fluctuations reaching 18.28%. Over the past year, it has decreased significantly, contrasting with the overall positive performance of the Sensex.

View All News